Evidence map›Paper›PMID 29948574›Full record

ArticleJournal of clinical immunology2018

T

Polina Stepensky, Baerbel Keller, Oded Shamriz, Caroline von Spee-Mayer, David Friedmann, Bella Shadur, Susanne Unger, Sebastian Fuchs, Adeeb NaserEddin, Nisreen Rumman and 7 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. A novel hypomorphic mutation inThe journal of allergy and clinical immunology. Global · 2025
    Article
  4. Article
  5. PreclinicalGenes & diseases · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 4 countries.

Polina StepenskyDepartment of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Hospital, POB 12000, 91200, Jerusalem, Israel. polina@hadassah.org.il.
Baerbel KellerCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Oded ShamrizPediatric Division, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Caroline von Spee-MayerCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
David FriedmannCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Bella ShadurDepartment of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Hospital, POB 12000, 91200, Jerusalem, Israel.
Susanne UngerCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Sebastian FuchsCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Adeeb NaserEddinDepartment of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Hospital, POB 12000, 91200, Jerusalem, Israel.
Nisreen RummanPediatric Department, Makassed Hospital, Jerusalem, Israel.
Sara AmroPediatric Department, Makassed Hospital, Jerusalem, Israel.
Vered Molho PessachDepartment of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Omar AbuzaitounNablus Specialty Hospital, Palestinian Authority, Nablus, Palestine.
Raz SomechPediatric Department A and the Immunology Services, "Edmond and Lily Safra" Children's Hospital, Jeffrey Modell Foundation Center, Sheba Medical Center, Tel Hashomer affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Orly ElpelegMonique and Jacques Roboh Department of Genetic Research, Hadassah, Hebrew University Medical Center, Jerusalem, Israel.
Stephan EhlCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Klaus WarnatzCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
University of Freiburg · DEHadassah Medical Center · ILHebrew University of Jerusalem · ILSpecialized Arab Hospital · PSTel Aviv University · ILUniversity Medical Center Freiburg · DEUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAll reported patients with hypomorphic X-linked severe combined immunodeficiency (X-SCID) due to c.664C>T (p.R222C) mutations in the gene (IL2RG) encoding the common γ chain (γc) have presented with opportunistic infections within the first year of life, despite the presence of nearly normal NK and T cell numbers. Reporting five children of one extended family with hemizygous mutations in IL2RG, we explore potential diagnostic clues and extend our comprehension of the functional impact of this mutation.

methodsWhole exome sequencing (WES); detailed immune phenotyping; cytokine-induced STAT phosphorylation; B, T, and NK cell activation; and quantification of sjTRECs in five Arab children with c.664C>T (p.R222C) IL2RG mutation.

resultsThe mean age at clinical presentation with respiratory tract infection or diarrhea was 6.8 (range: 2-12) months. None of the children presented with opportunistic infections. Diagnostic clues were early onset in the first year of life, and a suggestive family history associated with reduced naïve CD4 T cells and absent switched memory B cells. Number and phenotype of NK cells and innate-like lymphocytes were normal. The diagnosis was made by WES and corroborated by absent STAT phosphorylation and reduced functional response after IL-2 and IL-21 stimulation. Four patients underwent successful hematopoietic stem cell transplantation.

conclusionsAs early diagnosis and treatment are important, a high index of suspicion in the diagnosis of c.664C>T (p.R222C) X-SCID is needed. This requires prompt genetic testing by next generation sequencing in order to avoid unnecessary delays in the definite diagnosis since immunological work up may not be discriminating. Assays directly testing cytokine signaling or cytokine-dependent functions are helpful in confirming the functional impact of the identified hypomorphic variants.

Indexed as

MutationAdolescentAdultBiomarkersCell DifferentiationChildChild, PreschoolCytokinesDNA Mutational AnalysisFemaleGenetic TestingHumansImmunity, HumoralImmunophenotypingInterleukin Receptor Common gamma SubunitKiller Cells, NaturalBiomarkersCytokinesIL2RG protein, humanInterleukin Receptor Common gamma Subunitatypical SCIDcommon gamma chainIL2RGp.R222C mutationSevere combined immunodeficiencyX-SCID

Identifiers

PMID29948574
OpenAlexW2806275682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.